Phase 2 Study of AG-013736 in Patients With Refractory Metastatic Renal Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2015
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 24 Sep 2015 Results of effects of different degrees of renal impairment from one phase 3 and three phase 2 studies published in the Targeted Oncology.
- 13 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.